We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Comparison of Leakage With Nasal Prongs and Nasal Mask Interface in Newborns Receiving CPAP Treatment (ToNIL)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03586856
Recruitment Status : Completed
First Posted : July 16, 2018
Last Update Posted : November 13, 2019
Sponsor:
Information provided by (Responsible Party):
Baldvin Jonsson, Karolinska Institutet

Tracking Information
First Submitted Date  ICMJE June 4, 2018
First Posted Date  ICMJE July 16, 2018
Last Update Posted Date November 13, 2019
Actual Study Start Date  ICMJE August 1, 2018
Actual Primary Completion Date October 26, 2019   (Final data collection date for primary outcome measure)
Current Primary Outcome Measures  ICMJE
 (submitted: July 12, 2018)
Leakage in the CPAP system [ Time Frame: 0-60 min ]
Measurement of absolute leakage (at interface or mouth) using flowmeters connected to the CPAP device in flow through position (L/min, 30 seconds recording)
Original Primary Outcome Measures  ICMJE Same as current
Change History
Current Secondary Outcome Measures  ICMJE
 (submitted: July 12, 2018)
  • Inspired oxygen level (FiO2) [ Time Frame: 0-60 min ]
    FiO2 level and adjustments needed to maintain pre-intervention baseline peripheral oxygen saturation (SpO2 target range according to local guidelines)
  • Level of CPAP support (cmH2O) [ Time Frame: 0-60 min ]
    CPAP level and adjustments needed to maintain pre-intervention baseline peripheral oxygen saturation (SpO2 target range according to local guidelines)
  • Peripheral oxygen saturation (SpO2) [ Time Frame: 0-60 min ]
    Deviations from baseline and changes requiring adjustment of respiratory support (Outcome 2 and 3)
  • Measurement completion possible (yes/no) [ Time Frame: 0-60 min ]
    The number of infants (ratio of total included patients) where measurement of leakage could be determined (on first or more attempts)
  • Effect of simple measures to reduce leakage (L/min) [ Time Frame: 0-60 min ]
    Lowest level of recorded level of leakage obtainable using simple measures to reduce leakage, guided by leakage monitoring equipment (L/min and measures used to achieve reduction)
Original Secondary Outcome Measures  ICMJE Same as current
Current Other Pre-specified Outcome Measures
 (submitted: July 12, 2018)
  • Safety variable: Desaturation during measurement [ Time Frame: 0 to competition of measurement (maximum 3 hours) ]
    Desaturation (SpO2) from baseline requiring treatment or adjustment, during manipulation or leakage measurement.
  • Safety variable: Apneas during measurement [ Time Frame: 0 to competition of measurement (maximum 3 hours) ]
    Apneas requiring treatment or adjustment, during manipulation or leakage measurement.
  • Safety variable: FiO2 adjustments during measurement [ Time Frame: 0 to competition of measurement (maximum 3 hours) ]
    FiO2 adjustments required, during manipulation or leakage measurement.
  • Safety variable: Circulatory instability [ Time Frame: 0 to competition of measurement (maximum 3 hours) ]
    Circulatory instability (bradycardia or hypotension) requiring treatment or adjustment, during manipulation or leakage measurement.
  • Safety variable: Nasal irritation [ Time Frame: 0 to competition of measurement (maximum 3 hours) ]
    Nasal irritation requiring treatment or attention, during or after manipulation and leakage measurement.
  • Safety variable: Pneumothorax [ Time Frame: 0 to competition of measurement (maximum 3 hours) ]
    Confirmed pneumothorax or air-leak, during manipulation or leakage measurement.
  • Safety variable: Adverse events [ Time Frame: 0 to competition of measurement (maximum 3 hours) ]
    Problems related to trial or equipment used, classified as adverse events according to GCP (Good Clinical Practice)
  • Safety variable: Adherence to protocol [ Time Frame: 0 to competition of measurement (maximum 3 hours) ]
    Problems related to following study protocol
  • Safety variable: Problems with equipment [ Time Frame: 0 to competition of measurement (maximum 3 hours) ]
    Problems related to study equipment
Original Other Pre-specified Outcome Measures Same as current
 
Descriptive Information
Brief Title  ICMJE Comparison of Leakage With Nasal Prongs and Nasal Mask Interface in Newborns Receiving CPAP Treatment
Official Title  ICMJE Trial of NCPAP Interface Leakage (ToNIL): A Randomised Crossover Comparison of Leakage With Nasal Prongs and Nasal Mask Interface in Newborn Infants Treated With CPAP
Brief Summary

The study is a two-armed randomized cross-over comparison of leakage with nasal prongs and nasal mask interface in newborn infants treated with CPAP, born after 28 weeks of gestational age. For infants with an interface leakage, the trial also includes an observational part evaluating simple measures to reduce leakage.

The study will be carried out in the Karolinska University Hospital Stockholm and in the Östersund Hospital.

Detailed Description

The study will recruit a total of 50 infants receiving CPAP for respiratory support at the Karolinska University Hospital and the Östersund Hospital. The infant should be stable and not in major respiratory distress. Consent from the parents will be obtained before enrolment.

The included infants should have stable spontaneous breathing and be older than 28 weeks (corrected age) at the time of enrolment. The reason for respiratory failure and CPAP treatment is not relevant for study purposes. If an infant cannot participate in the study at a given time, he or she can be enrolled later. A child can only participate once.

The primary outcome is leakage. This is recorded using equipment for measuring air flow during CPAP treatment. Measurement of leakage is first performed for one interface and then the next (cross-over). The interface order is randomized. The leakage will be measured after a few minutes of stabilization (part 1). If there is leakage, a few simple measures to reduce the leakage will be evaluated (part 2). The second part will approximately add 10-20 minutes and includes simple measures such as adjusting the nasal mask, closing the mouth, changing the position or changing the size of nasal mask/prongs. Part 1 and part 2 are then repeated for the next interface. If the child shows signs of distress or agitation the measurement will be paused or stopped.

Part 1: The CPAP system with the randomized interface (nasal mask or nasal prongs) is applied and adjusted by experienced NICU staff. The staff is blinded for the outcome variable, leakage. The choice of size and other adjustments are guided by clinical experience and not by protocol. The NICU staff is not allowed to participate in the explorative part where measures to reduce leakage are evaluated. This precaution is to avoid staff learning what adjustments affect leakage and influence care of infants enrolled at a later stage.

Part 2: In this part the investigators can evaluate the effect of simple measures to minimize the leakage. The level of leakage is displayed on a screen. Examples of measures are; closing the mouth of the infant, adjusting straps, adjusting position and changing the size of the interface. Not every child will undergo all measures to reduce leakage, since the aim of this explorative part is to explore ways to reduce leakage.

It is estimated that these tests and measures will take 15-60 minutes per child. No other measurements or follow-up is planned. No blood samples will be collected or analysed.

The study will collect information on the infant and the birth. This includes birth weight, gestational age at birth, gender, previous respiratory support and medical history.

The main outcome variable is absolute leakage (via mouth or via CPAP interface). Other collected variables are oxygen saturation, respiratory rate, inspired oxygen concentration, apneas, heart rate, if the infant is awake/asleep or in distress. Safety variables include skin irritation or damage of the nose caused by the interface, instability or deterioration of respiration or circulation, problems with the equipment or other adverse events. The investigation can be stopped immediately in the case of distress or instability. The study is, as far as the investigators know, the first one of its kind. The air flow meters do not affect the CPAP system and use a technique that measures the total leakage in L/min. These improvements have been emphasized in previous studies. The study follows GCP (good clinical practice) standards and The Helsinki declaration.

Study Type  ICMJE Interventional
Study Phase  ICMJE Not Applicable
Study Design  ICMJE Allocation: Randomized
Intervention Model: Crossover Assignment
Intervention Model Description:
Main study design: Two armed randomized cross-over comparison of leakage for two interfaces. The trial also investigates simple measures to reduce leakage (observational)
Masking: None (Open Label)
Primary Purpose: Treatment
Condition  ICMJE
  • Respiration; Insufficient or Poor, Newborn
  • Infant,Premature
Intervention  ICMJE
  • Device: Nasal mask interface
    Nasal masks is a standard interface used for CPAP treatment of newborn infants. The CPAP device allows for easily switching between the nasal prongs or nasal mask interface as well as adjustment of size.
  • Device: Nasal prongs interface
    Nasal masks is a standard interface used for CPAP treatment of newborn infants. The CPAP device allows for easily switching between the nasal prongs or nasal mask interface as well as adjustment of size.
Study Arms  ICMJE
  • Active Comparator: Nasal mask interface
    The CPAP interface will be applied and adjusted by experienced staff blinded to the outcome variable; leakage. Measures to reduce/minimize leakage are tested in an unblinded observational part after the intervention.
    Intervention: Device: Nasal mask interface
  • Active Comparator: Nasal prongs interface
    The CPAP interface will be applied and adjusted by experienced staff blinded to the outcome variable; leakage. Measures to reduce/minimize leakage are tested in an unblinded observational part after the intervention.
    Intervention: Device: Nasal prongs interface
Publications * Gunnarsdottir K, Falk M, Baldursdottir S, Donaldsson S, Jonsson B, Drevhammar T. Do newborn infants exhale through the CPAP system? Secondary analysis of a randomised cross-over trial. Arch Dis Child Fetal Neonatal Ed. 2022 Oct 19:fetalneonatal-2022-324462. doi: 10.1136/archdischild-2022-324462. Online ahead of print.

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Completed
Actual Enrollment  ICMJE
 (submitted: July 12, 2018)
50
Original Estimated Enrollment  ICMJE Same as current
Actual Study Completion Date  ICMJE October 26, 2019
Actual Primary Completion Date October 26, 2019   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

  • Gestational age over 28 weeks (corrected age) at the time of inclusion
  • Patient receiving respiratory support with CPAP

Exclusion Criteria:

  • Airway, pulmonary, cardiac or gastro-intestinal malformations
  • Neuromuscular disease
  • Circulatory unstable patient
  • FiO2 higher than 0.5
  • Nasal damage or major skin irritation.
  • Extubation less than 24 h before investigation
  • Surgery less than 5 days before investigation
Sex/Gender  ICMJE
Sexes Eligible for Study: All
Ages  ICMJE up to 44 Weeks   (Child)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE Contact information is only displayed when the study is recruiting subjects
Listed Location Countries  ICMJE Sweden
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT03586856
Other Study ID Numbers  ICMJE 2016/2449-31
Has Data Monitoring Committee No
U.S. FDA-regulated Product
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
IPD Sharing Statement  ICMJE
Plan to Share IPD: Undecided
Current Responsible Party Baldvin Jonsson, Karolinska Institutet
Original Responsible Party Same as current
Current Study Sponsor  ICMJE Baldvin Jonsson
Original Study Sponsor  ICMJE Same as current
Collaborators  ICMJE Not Provided
Investigators  ICMJE
Principal Investigator: Baldvin Jonsson, MD, PhD Karolinska Institutet
PRS Account Karolinska Institutet
Verification Date November 2019

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP